Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;40(4):491-504.
doi: 10.1002/hon.2987. Epub 2022 Apr 15.

Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies

Tariq I Mughal  1   2 , Naveen Pemmaraju  3 , Rafael Bejar  4 , Robert P Gale  5 , Prithviraj Bose  3 , Jean-Jacques Kiladjian  6 , Josef Prchal  7 , Daniel Royston  8 , Daniel Pollyea  9 , Peter Valent  10   11 , Tim H Brümmendorf  12 , Tomasz Skorski  13 , Mrinal Patnaik  14 , Valeria Santini  15 , Pierre Fenaux  16 , Nicole Kucine  17 , Srdan Verstovsek  3 , Ruben Mesa  18 , Tiziano Barbui  19 , Guiseppe Saglio  20 , Richard A Van Etten  21
Affiliations
Review

Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies

Tariq I Mughal et al. Hematol Oncol. 2022 Oct.

Abstract

Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15th Post-American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th-10th December 2020 and 7th-10th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.

Keywords: Myelofibrosis; chronic myeloid leukemia; clinical; systemic mastocytosis; thrombosis; translational.

PubMed Disclaimer

References

REFERENCES

    1. Druker B. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(3):4808-4817.
    1. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
    1. Brkic S, Meyer SC. Challenges and perspective for therapeutic targeting of myeloproliferative neoplasms. HemaSphere. 2021;5(1):e516.
    1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
    1. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391-2405.